Cube Biotech GmbH

Cube Biotech GmbH is a specialized German biotechnology company founded in 2012 in Monheim, Germany, by a team of experienced researchers in biology, biochemistry, and organic chemistry with over 40 years of collective expertise in membrane protein research. The company has established itself as a pioneer in membrane protein production and purification technologies, addressing one of the most challenging aspects of drug discovery research. Headquartered in Monheim with a subsidiary in Wayne, Pennsylvania, Cube Biotech operates as a contract research organization providing non-GMP services for pharmaceutical, biotechnology, and academic customers worldwide. The company's core specialty lies in the stable extraction and purification of membrane proteins, which are critical drug targets found across cell surfaces but are extremely difficult to extract without losing native functionality. Cube Biotech's proprietary technologies include a vast synthetic copolymer portfolio, high-quality purification resins, membrane protein stabilization kits, nanodiscs, magnetic beads, protein purification matrices, cell-free lysates, and ultrapure detergents. The company provides comprehensive services including membrane protein expression, purification, crystallization, biophysical target characterization, structure determination by cryo-EM, and assay development. With approximately 49 employees and annual revenues of $18.5 million, Cube Biotech operates a dual business model combining service offerings that generate milestone payments with product sales providing consistent revenue streams. In November 2021, the company was acquired by ARCHIMED, a transatlantic private equity healthcare specialist, through its MED II fund, marking a successful exit for early investor Creathor Ventures who backed the company since 2012. In January 2025, Cube Biotech completed a transformational acquisition of IBA Lifesciences GmbH, significantly expanding its capabilities and market position in affinity-tag purification technologies and positioning the combined entity as a comprehensive provider of protein research solutions for the global biopharma research market.